Atlas Trials

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

Clinical trial NCT04126733 · COMPLETED

Trial details

NCT number
NCT04126733
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Colorectal Cancer
Start date
2019-10-14
Primary completion
2020-11-11
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.